逆转录病毒载体介导的RNA干扰稳定抑制肌肉生长抑制素GDF-8的表达

为将肌肉生长抑制素的干扰序列表达盒hU6-siGDF-8有效导入肌成纤维细胞C2C12中, 以pAV-hU6 + 27载体为基础构建逆转录病毒载体pXSN-hU6-siGDF-8, 并使之与pVSV-G质粒共转染GP-293细胞, 用包装出的病毒粒子感染宿主细胞C2C12, G418筛选稳定整合逆转录病毒的抗性细胞库。2周后, Western Blotting和Real-Time PCR分析结果显示, 细胞内源性的GDF-8基因的表达得到了有效的抑制; MTT法和细胞流式仪分析表明, G418抗性细胞得到了更有效的增殖, 并且G0/G1期细胞数量减少了13.7%, S期细胞数量增加了14.9%。因此, 逆转录病毒载体的RNA干扰系统可以稳定抑制 GDF-8基因表达, 它将成为治疗肌肉萎缩疾病的一个强有力的工具。     

一种具有G418抗性筛选标记的慢病毒RNA干扰表达载体的构建及应用

目的:构建具有新霉素抗性筛选标记的RNA干扰慢病毒表达载体,并检测它对乙型肝炎病毒x基因(HBx mRNA表达的抑制作用。方法:从pcDNA3.0载体中扩增新霉素抗性基因并插入删除嘌呤霉素编码序列的pLKO载体中;将改构的RNA干扰载体包装成慢病毒后感染肝癌细胞HepG2,并检测感染细胞对G418的抵抗作用;为验证改构RNA干扰载体的有效性,设计了2条针对HBx的RNA干扰序列以及针对编码萤光素酶cDNA的干扰序列并插入该载体,将含新霉素筛选标记的HBx的RNA干扰载体与辅助质粒在293T细胞中包装成慢病毒并感染过表达HBx的HepG2(嘌呤霉素抗性)细胞,运用G418筛选出稳定混合克隆,提取细胞总RNA,运用RT-qPCR检测其在HepG2细胞中对HBx RNA表达的抑制作用。结果:构建的载体与辅助质粒包装出的慢病毒感染肝癌细胞后,细胞获得G418抗性;HBx RNA干扰序列克隆入该载体可有效抑制肝癌细胞中过量表达的HBx mRNA。结论:构建了具有新霉素抗性筛选标记的RNA干扰慢病毒表达载体,运用该载体可有效筛选出抑制目的基因表达的G418抗性的稳定细胞株。     

用pLNCX2携带人MCPH1基因shRNA重组逆转录病毒载体的构建及鉴定

目的建立逆转录病毒介导的MCPH1基因RNA干扰表达体系并观察其在宫颈癌Caski细胞中对MCPH1表达的影响。方法将人MCPH1基因RNA干扰双链DNA片段重组到逆转录病毒质粒pLNCX2中,构建携带人MCPHI基因RNA干扰的逆转录病毒载体pLNCX2-shRNA—MCPH1,经PT67细胞包装后,产生的重组逆转录病毒感染宫颈癌细胞株Caski细胞,并用G418筛选产生稳定的细胞克隆,用RT—PCR和Western印迹检测细胞中MCPH1mRNA和蛋白表达的变化。结果重组逆转录病毒质粒经测序鉴定正确,逆转录病毒感染Caski细胞后用G418筛选出稳定的细胞克隆,RT—PCR和Western印迹检测人MCPH1mRNA和蛋白表达水平明显低于阴性对照组和未干扰组。结论携带人MCPHI基因RNA干扰双链DNA片段的逆转录病毒感染Caski细胞后能明显抑制MCPHImRNA和蛋白表达,为进一步研究MCPH1在宫颈癌中的作用奠定了基础。     

Pmscv-Ubc9逆转录病毒表达载体的构建及产毒细胞系的建立

目的：构建含Ubc9的逆转录病毒表达载体,筛选建立携带该基因的高滴度产毒细胞系,深入研究SUMO化修饰的作用。方法：聚合酶链反应（PCR）扩增获取目的基因Ubc9,定向插入逆转录病毒表达载体pMSCVneo,形成重组质粒pMSCV-Ubc9;脂质体法将pMSCV-Ubc9转染逆转录病毒包装细胞PT67;G418筛选产毒细胞克隆,扩大培养产毒细胞克隆,收获病毒感染NIH3T3细胞。结果：限制性酶切和测序鉴定证实Ubc9正确插入逆转录病毒表达载体。G418筛选获得稳定产毒的抗性细胞克隆,收获病毒能有效感染NIH3T3细胞。结论：携带Ubc9基因的重组逆转录病毒表达载体pMSCV-Ubc9构建成功,转染PT67细胞后包装出重组逆转录病毒,进而筛选获得了能转录表达Ubc9的产毒细胞系PT67-Ubc9。     

Pmscv-Ubc9 逆转录病毒表达载体的构建及产毒细胞系的建立

目的:构建含Ubc9的逆转录病毒表达载体,筛选建立携带该基因的高滴度产毒细胞系,深入研究SUMO化修饰的作用。方法:聚合酶链反应(PCR)扩增获取目的基因Ubc9,定向插入逆转录病毒表达载体pMSCVneo,形成重组质粒pMSCV-Ubc9;脂质体法将pMSCV-Ubc9转染逆转录病毒包装细胞PT67;G418筛选产毒细胞克隆,扩大培养产毒细胞克隆,收获病毒感染NIH3T3细胞。结果:限制性酶切和测序鉴定证实Ubc9正确插入逆转录病毒表达载体。G418筛选获得稳定产毒的抗性细胞克隆,收获病毒能有效感染NIH3T3细胞。结论:携带Ubc9基因的重组逆转录病毒表达载体pMSCV-Ubc9构建成功,转染PT67细胞后包装出重组逆转录病毒,进而筛选获得了能转录表达Ubc9的产毒细胞系PT67-Ubc9。     

锤头状核酶在HepG2细胞中抑制adr亚型的乙型肝炎病毒

针对HBV基因组设计了三种锤头状核酶－－RS3、RC2和RC1。将裸露的和用tRNA包埋的核酶（RtS3、RtC2和RtC1）基因插入RNA修剪质粒pRG523中,然后转变为真核表达载体,使用同样克隆技术,构建由不同长度（2、4、8、12个）RS3或12个RtS3连成的鸟枪型真核表达载体,将它们分别与带有HBV基因组的质粒共转染人肝癌细胞系HepG2,用G418筛选抗性细胞。分析不同种类的核酶在G418抗性细胞中的HBV抑制活性,包括子代HBV－DNA、HBV－RNA和抗原（HBsAg或HBcAg/HBeAg)表达的减少。结果表明,所有设计的核酶对HBV有＞70％的抑制活性,而tRNA包埋核酶的活性略高于裸露核酶。特别值得提出的是,由8个或12个相同核酶连接的鸟枪型质粒（8RS3、12RS3和12RsS3）具有很高的抑制HBV活性,达到＞9－％的抑制。     

鼻咽癌CD44抑制表达细胞株的建立

目的:构建CD44新剪接变异体siRNA质粒表达载体,建立CD44新变异体抑制表达的鼻咽癌细胞株.方法:合成CD44新变异体特异性干扰DNA片段,干扰DNA片段亚克隆于带绿色荧光蛋白的pGenesil -1.3质粒表达载体中,双酶切和测序鉴定重组表达质粒载体;采用脂质体将重组表达质粒载体转染入鼻咽癌5 -8F细胞系,进行G418筛选;Western blot分析CD44表达.结果:重组CD44干扰DNA片段质粒表达载体的碱基序列和插入方向正确;细胞转染效率达70％;G418筛选获得GFP表达的单克隆鼻咽癌5 -8F细胞株;Western blot分析表明CD44表达受抑制.结论:建立了CD44新变异体抑制表达的鼻咽癌细胞株,为CD44新变异体在鼻咽癌中的生物学功能提供了基础.     

小鼠肌肉生长抑制素基因短发夹RNA促进MyoD在C2C12细胞中的表达

肌肉生长抑制素(myostatin,MSTN)属于转化生长因子-β(transforming growth factor-β,TGF-β)超家族,主要功能为负向调节骨骼肌的生长.肌肉生长抑制素基因敲除小鼠肌肉出现显著增加,而将干涉该基因的短发夹RNA注射并电击转化入大鼠胫前肌则引起肌肉重量、肌纤维以及MHCⅡ表达的增加.通过与小鼠肌肉生长抑制素基因表达载体共转染HEK293细胞,筛选到两条能够高效抑制小鼠肌肉生长抑制素基因表达的小干涉RNA.构建了这两条小RNA的表达载体Mst-shRNA1和Mst-shRNA2,用其分别转染小鼠C2C12成肌细胞,并通过G418药物筛选和流式细胞仪富集整合了短发夹RNA表达载体的阳性细胞.通过采用Real-time PCR和Western blot分析,检测到在分别整合了Mst-shRNA1和Mst-shRNA2的C2C12细胞中,内源性肌肉生长抑制素基因的mRNA水平分别下降了10.2%和35.5%,蛋白质表达则分别下降了29.3%和64.7%.同时,在这两组中MyoD的表达上升了24.4%和40.4%,证明通过RNA干涉实现的肌肉生长抑制素基因的抑制导致了下游MyoD基...     

大鼠Pael -R基因shRNA干扰载体的构建及功能筛选鉴定

目的:构建并筛选针对大鼠Pael -R基因的有效shRNA干扰载体并鉴定其干扰效果.方法:构建三个针对大鼠Pael-R基因的shRNA表达载体,利用脂质体转染大鼠肾上腺嗜铬细胞瘤细胞PC12,以G418筛选抗性细胞克隆并利用RT-PCR和Western Blotting鉴定Pael -R基因的表达.结果:在构建的3个干扰载体中,转染pRNA-U6/PaelR -3的细胞克隆中Pael -R表达在mRNA水平为29％,与对照组相比下降了45.3％,在蛋白质水平为32％,下降了27.3％ (P＜0.05).结论:构建了Pael -R基因的有效干扰载体pRNA-U6/PaelR -3,并得到了Pael -R基因表达下调型PC12细胞克隆,为研究Pael -R基因表达下调在帕金森病的发病机制及其治疗中的作用奠定了基础.     

人Sema4C重组腺病毒载体的构建及其在小鼠成肌细胞系C2C12中的表达

利用Ad5腺病毒载体系统构建人Sema4C基因重组腺病毒表达载体并在成肌细胞系C2C12中表达,并初步探讨Sema4C基因在成肌发育过程中的可能作用。利用脂质体介导重组腺病毒载体转染HEK293细胞,包装出完整的腺病毒;将重组腺病毒载体感染C2C12成肌细胞后,利用激光共聚焦显微镜观察发现12h即有绿色荧光表达,24h后绿色荧光蛋白表达最强;流式细胞仪检测病毒的感染效率几乎达100%。WB检测结果表明感染重组腺病毒载体组C2C12细胞Sema4C蛋白的表达量明显高于空载体对照组（P<0.01）。为了进一步观察Sema4C基因对C2C12细胞增殖分化的影响,流式细胞仪检测了病毒感染48h后C2C12细胞的增殖指数,并对感染后诱导分化的C2C12细胞的分化情况进行了观察。我们的结果首次表明,过表达外源性人Sema4C基因不仅能使C2C12细胞的G0/G1期比例增加,细胞的增殖指数下降,同时在分化培养条件下还能促进C2C12细胞肌管的形成。     

鸡生长分化因子GDF—8cDNA的克隆、表达及蛋白纯化

Growth and Differentiation Factor-8(GDF-8) is a new member of TGF-beta super-family. It has been shown that GDF-8 is specifically expressed in skeleton muscle in mouse and its function is to inhibit the growth of muscle cell, so it is named as Myostatin. Here, we amplified 3'half-length GDF-8 cDNA from chicken skeleton muscle by RT-PCR, and cloned it into the prokaryotic expression vector pTrcHisB, which was then transformed into E. coli Top10 cells. The recombinant 6 x His-GDF-8 fusion protein expressed in the Top10 cells was purified by Ni(+)-Affinity Chromatography for future study.     

牛α-IFN及FMDV P12A3C双表达载体的构建及其在BHK-21细胞中的表达

从口蹄疫病毒Asia I/Jiangsu毒株的细胞毒中提取总RNA,通过RT-PCR方法分别获得FMDV的P12A及3C基因;同时以pMD18-T-α-IFN质粒为模板,PCR扩增得到α-IFN基因.将α-IFN基因及FMDV P12A及3C基因连接至双启动子表达载体pBudCE4.1上,构建成双效表达质粒pBudCE4.1-α-IFN-P12A3C,经电泳、PCR、双酶切和DNA测序鉴定表明双效质粒载体构建成功.用此重组质粒转染BHK-21细胞后并对其表达情况进行检测,表明该双表达质粒在BHK-21细胞中能够成功表达.以此重组质粒免疫乳鼠后12 h,按100 TCID50/O.1 mL的量进行攻毒,结果发现该质粒能够抑制病毒的增殖,对乳鼠有一定的保护作用.结果表明成功构建了牛α-IFN及FMDV P12A3C组合基因双表达载体,为进一步研究口蹄疫基因疫苗提供前期基础.     

丙型肝炎病毒NS5A蛋白对Huh7细胞周期的影响

应用PCR技术从含有丙型肝炎病毒（HCV）全长开放阅读框的质粒pBRTM／HCV1～3011中获得NS5A全长基因片段,利用基因重组技术将其克隆至真核表达载体pcDNA3．1（-）中。通过酶切、PCR及测序鉴定证实,NS5A基因已正确插入到pcDNA3．1（-）中。再利用脂质体介导转染Huh7细胞,30h后收获细胞,经Western blot验证,证实HCV的NS5A基因在Huh7细胞中已经获得表达。在培养条件完全一致的条件下,表达NS5A基因的Huh7细胞与pcDNA3．1（-）转染的细胞在转染30h后被收集起来,乙醇固定,PI染色后利用流式细胞仪检测细胞周期变化。G0／G1期由60．6％下降到49．7％,S期由23．9％上升到32．7％,而转染pcDNA3．1（-）细胞的细胞周期与正常的Huh7细胞则差别不大。从而证明HCV NS5A蛋白对Huh7细胞周期具有调节作用。     

在昆虫细胞中表达G2型轮状病毒地方株VP7基因

Ａ组轮状病毒是导致婴幼儿重症腹泻的最主要病毒病原,ＶＰ７是病毒外壳上的主要糖蛋白,它具有中和抗原活性,与病毒的毒力及免疫保护性有关,也是划分病毒血清型的最主要标志之一〔１〕。ＶＰ７基因及其编码蛋白一直是人们研究的主要对象,很多研究工作和诊断试剂都需大...     

Osteogenic protein-1 (OP-1, BMP-7) induces osteoblastic cell differentiation of the pluripotent mesenchymal cell line C2C12

The effects of Osteogenic Protein-1 (OP-1, BMP-7) on the differentiation of the pluripotent mesenchymal cell line, C2C12, were examined. OP-1 at 50 ng/ml partially inhibited myotube formation in C2C12 cells, while OP-1 at 200 ng/ml completely inhibited myotube formation and induced the formation of cells displaying osteoblastic morphology. High concentrations of OP-1 elevated the alkaline phosphatase (AP) activity dramatically, both as a function of time and OP-1 concentration. Osteocalcin (OC) mRNA expression was detected as early as 8 days in OP-1-treated cultures and subsequently increased considerably. Expression of bone sialoprotein (BSP) mRNA was low in control cultures and stimulated by OP-1. Collagen type I mRNA expression was enhanced by OP-1 during the early days in culture, but gradually decreased thereafter. MyoD mRNA expression, high in control cultures, was suppressed by OP-1 in a dose- and time-dependent manner. OP-1 enhanced ActR-I mRNA expression and significantly elevated the mRNA expressions of BMP-1, BMP-4, BMP-5, GDF-6, and GDF-8. The present results indicate that OP-1 is a potent inducer of C2C12 differentiation into osteoblastic cells.     

Expression, purification and osteogenic bioactivity of recombinant human BMP-4, -9, -10, -11 and -14

Bone morphogenetic proteins (BMPs) are cytokines from the TGF-β superfamily, with important roles during embryonic development and in the induction of bone and cartilage tissue differentiation in the adult body. In this contribution, we report the expression of recombinant human BMP-4, BMP-9, BMP-10, BMP-11 (or growth differentiation factor-11, GDF-11) and BMP-14 (GDF-5), using Escherichia coli pET-25b vector. BMPs were overexpressed, purified by affinity his-tag chromatography and shown to induce the expression of early markers of bone differentiation (e.g. smad-1, smad-5, runx2/cbfa1, dlx5, osterix, osteopontin, bone sialoprotein and alkaline phosphatase) in C2C12 cells and in human adipose stem cells. The described approach is a promising method for producing large amounts of different recombinant BMPs that show potential for novel biomedical applications.     

人GDNF在甲醇酵母及家蚕幼虫中的表达

将人胶质细胞源性神经营养因子(GDNF)基因克隆入酵母分泌型表达载体pPIC9K中,酶切线性化后电穿孔导入酵母细胞进行整合,经G418筛选得到多拷贝转化子,甲醇诱导表达。将人GDNF基因克隆入昆虫病毒转移载体pBacPAK8中,与线性化Bm-BacPAK6修饰病毒基因组DNA共转染家蚕细胞,经体内重组,筛选到重组病毒。用重组病毒感染家蚕幼虫,5d后收集血淋巴。SDS-PAGE和蛋白质印迹杂交结果证实了酵母培养上清液及家蚕幼虫血淋巴中含有GDNF蛋白。活性研究表明,甲醇酵母及家蚕幼虫表达的GDNF蛋白能促进多巴胺能神经元的存活和突起生长。     

Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells.

The cellular receptors that mediate binding and internalization of retroviruses have recently been identified. The concentration and accessibility of these receptors are critical determinants in accomplishing successful gene transfer with retrovirus-based vectors. Murine retroviruses containing ecotropic glycoproteins do not infect human cells since human cells do not express the receptor that binds the ecotropic glycoproteins. To enable human cells to become permissive for ecotropic retrovirus-mediated gene transfer, we have developed a recombinant adeno-associated virus type 2 (AAV) vector containing ecotropic retroviral receptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter (vRSVp-ecoR). Established human cell lines, such as HeLa and KB, known to be nonpermissive for murine ecotropic retroviruses, became permissive for infection by a retroviral vector containing a bacterial gene for resistance to neomycin (RV-Neo(r)), with a transduction efficiency of up to 47%, following transduction with vRSVp-ecoR, as determined by the development of colonies that were resistant to the drug G418, a neomycin analog. No G418-resistant colonies were present in cultures infected with either vRSVp-ecoR or RV-Neo(r) alone. Southern and Northern blot analyses revealed stable integration and long-term expression, respectively, of the transduced murine ecoR gene in clonal isolates of HeLa and KB cells. Similarly, ecotropic retrovirus-mediated Neo(r) transduction of primary human CD34+ hematopoietic progenitor cells from normal bone marrow was also documented, but only following infection with vRSVp-ecoR. The retroviral transduction efficiency was approximately 7% without prestimulation and approximately 14% with prestimulation of CD34+ cells with cytokines, as determined by hematopoietic clonogenic assays. No G418-resistant progenitor cell colonies were present in cultures infected with either vRSVp-ecoR or RV-Neo(r) alone. These results suggest that sequential transduction of primary human cells with two different viral vectors may overcome limitations encountered with a single vector. Thus, the combined use of AAV- and retrovirus-based vectors may have important clinical implications for ex vivo and in vivo human gene therapy.